Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 941

1.

Highlights from Gastro Update Europe - Budapest June 26-27, 2019.

Tytgat GNJ.

Arab J Gastroenterol. 2019 Sep;20(3):148-162. doi: 10.1016/j.ajg.2019.09.002. Epub 2019 Sep 27. No abstract available.

PMID:
31570302
2.

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.

Peinemann F, van Dalen EC, Enk H, Tytgat GA.

Cochrane Database Syst Rev. 2019 Apr 24;4:CD012442. doi: 10.1002/14651858.CD012442.pub2.

PMID:
31016728
3.

Plasma free metanephrines for diagnosis of neuroblastoma patients.

Barco S, Verly I, Corrias MV, Sorrentino S, Conte M, Tripodi G, Tytgat G, van Kuilenburg A, van der Ham M, de Sain-van der Velden M, Garaventa A, Cangemi G.

Clin Biochem. 2019 Apr;66:57-62. doi: 10.1016/j.clinbiochem.2019.02.012. Epub 2019 Feb 26.

PMID:
30822416
4.

Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients.

Verly IRN, Leen R, Meinsma JR, Hooijer GKJ, Savci-Heijink CD, van Nes J, Broekmans M, Wanders RJA, van Kuilenburg ABP, Tytgat GAM.

Eur J Cancer. 2019 Apr;111:21-29. doi: 10.1016/j.ejca.2019.01.014. Epub 2019 Feb 22.

PMID:
30798085
5.

An Interactive Web-Based Educational Tool Improves Detection and Delineation of Barrett's Esophagus-Related Neoplasia.

Bergman JJGHM, de Groof AJ, Pech O, Ragunath K, Armstrong D, Mostafavi N, Lundell L, Dent J, Vieth M, Tytgat GN, Sharma P; International Working Group for Classification of Oesophagitis.

Gastroenterology. 2019 Apr;156(5):1299-1308.e3. doi: 10.1053/j.gastro.2018.12.021. Epub 2019 Jan 2.

PMID:
30610858
6.

Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.

Popov A, Druy A, Shorikov E, Verzhbitskaya T, Solodovnikov A, Saveliev L, Tytgat GAM, Tsaur G, Fechina L.

J Cancer Res Clin Oncol. 2019 Feb;145(2):535-542. doi: 10.1007/s00432-018-02831-w. Epub 2019 Jan 2.

PMID:
30603901
7.

Gastro Update Europe 2018.

Tytgat GNJ.

Dig Dis. 2019;37(3):175-187. doi: 10.1159/000495705. Epub 2019 Jan 2. No abstract available.

8.

Highlights from Gastro Update Europe - Prague, June 2018.

Tytgat GNJ.

Arab J Gastroenterol. 2018 Dec;19(4):159-165. doi: 10.1016/j.ajg.2018.09.002. Epub 2018 Nov 30. No abstract available.

PMID:
30509761
9.

Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution.

Kraal KCJM, Timmerman I, Kansen HM, van den Bos C, Zsiros J, van den Berg H, Somers S, Braakman E, Peek AML, van Noesel MM, van der Schoot CE, Fiocco M, Caron HN, Voermans C, Tytgat GAM.

Clin Cancer Res. 2019 Feb 1;25(3):1012-1021. doi: 10.1158/1078-0432.CCR-18-1904. Epub 2018 Oct 12.

PMID:
30314967
10.

Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

Druy AE, Shorikov EV, Tsaur GA, Popov AM, Zaychikov AN, Tuponogov SN, Saveliev LI, Tytgat GAM, Fechina LG.

Pediatr Blood Cancer. 2018 Nov;65(11):e27354. doi: 10.1002/pbc.27354. Epub 2018 Jul 14.

PMID:
30007008
11.

3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.

Verly IRN, van Kuilenburg ABP, Abeling NGGM, Goorden SMI, Fiocco M, Vaz FM, van Noesel MM, Zwaan CM, Kaspers GJL, Merks JHM, Caron HN, Tytgat GAM.

Eur J Cancer. 2018 Feb;90:102-110. doi: 10.1016/j.ejca.2017.11.025. Epub 2017 Dec 21.

PMID:
29274926
12.

Highlights from Gastro Update Europe - Vienna April 6-8, 2017.

Tytgat GNJ.

Arab J Gastroenterol. 2017 Sep;18(3):174-188. doi: 10.1016/j.ajg.2017.09.009. Epub 2017 Oct 4. No abstract available.

PMID:
28988789
13.

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, van Dijk-Kerkhoven L, Huizer-Smit M, Lecca MC, Chan A, Lakeman A, Molenaar P, Volckmann R, Westerhout EM, Hamdi M, van Sluis PG, Ebus ME, Molenaar JJ, Tytgat GA, Westerman BA, van Nes J, Versteeg R.

Nat Genet. 2017 Aug;49(8):1261-1266. doi: 10.1038/ng.3899. Epub 2017 Jun 26.

PMID:
28650485
14.

Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL.

Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349. doi: 10.1002/14651858.CD010349.pub2. Review.

15.

Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA.

Eur J Cancer. 2017 May;76:188-196. doi: 10.1016/j.ejca.2016.12.013. Epub 2017 Mar 19.

PMID:
28329731
16.

A phantom study: Should 124 I-mIBG PET/CT replace 123 I-mIBG SPECT/CT?

Beijst C, de Keizer B, Lam MGEH, Janssens GO, Tytgat GAM, de Jong HWAM.

Med Phys. 2017 May;44(5):1624-1631. doi: 10.1002/mp.12202. Epub 2017 Apr 17.

PMID:
28273347
17.

Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review.

Kraal K, Blom T, van Noesel M, Kremer L, Caron H, Tytgat G, van der Pal H.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26451. Epub 2017 Feb 2. Review.

PMID:
28150396
18.

Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients.

Verly IR, van Kuilenburg AB, Abeling NG, Goorden SM, Fiocco M, Vaz FM, van Noesel MM, Zwaan CM, Kaspers GL, Merks JH, Caron HN, Tytgat GA.

Eur J Cancer. 2017 Feb;72:235-243. doi: 10.1016/j.ejca.2016.12.002. Epub 2017 Jan 4.

PMID:
28061374
19.

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.

Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F.

Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. Review.

20.

Highlights from Gastro Update Europe - Prague, April 29-30, 2016.

Tytgat GN.

Arab J Gastroenterol. 2016 Sep;17(3):146-152. doi: 10.1016/j.ajg.2016.08.002. Epub 2016 Sep 17. No abstract available.

PMID:
27651136
21.

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.

Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanić G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O'Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K.

J Clin Oncol. 2016 Sep 10;34(26):3195-203. doi: 10.1200/JCO.2015.66.0001. Epub 2016 Jul 18. Erratum in: J Clin Oncol. 2017 Jun 20;35(18):2100.

22.

Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

van Wezel EM, Decarolis B, Stutterheim J, Zappeij-Kannegieter L, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, van Noesel MM, Caron HN, van der Schoot CE, Hero B, Tytgat GAM.

Eur J Cancer. 2016 Feb;54:149-158. doi: 10.1016/j.ejca.2015.11.007. Epub 2016 Jan 12.

PMID:
26796600
23.

Highlights from Gastro Update Europe: Budapest, June 12-13, 2015.

Tytgat GN.

Arab J Gastroenterol. 2015 Sep-Dec;16(3-4):150-6. doi: 10.1016/j.ajg.2015.09.003. Epub 2015 Nov 21. No abstract available.

PMID:
26611764
24.

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.

Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GA, Molenaar JJ, Versteeg R.

Nat Genet. 2015 Dec;47(12):1411-4. doi: 10.1038/ng.3438. Epub 2015 Nov 2.

PMID:
26523776
25.

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, van Dalen EC.

Cochrane Database Syst Rev. 2015 Sep 29;(9):CD009263. doi: 10.1002/14651858.CD009263.pub2. Review.

26.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

27.

Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.

Kraal KC, Tytgat GA, van Eck-Smit BL, Kam B, Caron HN, van Noesel M.

Pediatr Blood Cancer. 2015 Nov;62(11):1886-91. doi: 10.1002/pbc.25580. Epub 2015 May 15.

PMID:
25981988
28.

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

van Wezel EM, Stutterheim J, Vree F, Zappeij-Kannegieter L, Decarolis B, Hero B, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, Voermans C, van Noesel MM, Caron HN, van der Schoot CE, Tytgat GA; GPOH MRD Study Group.

Pediatr Blood Cancer. 2015 Aug;62(8):1368-73. doi: 10.1002/pbc.25507. Epub 2015 May 4.

PMID:
25939774
29.

Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.

Wegert J, Ishaque N, Vardapour R, Geörg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, Keller A, Grimm C, Kneitz S, Williams RD, Chagtai T, Pritchard-Jones K, van Sluis P, Volckmann R, Koster J, Versteeg R, Acha T, O'Sullivan MJ, Bode PK, Niggli F, Tytgat GA, van Tinteren H, van den Heuvel-Eibrink MM, Meese E, Vokuhl C, Leuschner I, Graf N, Eils R, Pfister SM, Kool M, Gessler M.

Cancer Cell. 2015 Feb 9;27(2):298-311. doi: 10.1016/j.ccell.2015.01.002.

30.

Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).

Mavinkurve-Groothuis AM, van den Heuvel-Eibrink MM, Tytgat GA, van Tinteren H, Vujanic G, Pritchard-Jones KL, Howell L, Graf N, Bergeron C, Acha T, Catania S, Spreafico F.

Pediatr Blood Cancer. 2015 Apr;62(4):598-602. doi: 10.1002/pbc.25357. Epub 2014 Dec 29.

PMID:
25546733
31.

Reflections on esophageal columnar metaplasia (Barrett)-ANNO 2015.

Tytgat GN.

J Dig Dis. 2015 Feb;16(2):55-7. doi: 10.1111/1751-2980.12224.

PMID:
25529483
32.

Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.

Clement SC, van Rijn RR, van Eck-Smit BL, van Trotsenburg AS, Caron HN, Tytgat GA, van Santen HM.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):706-15. doi: 10.1007/s00259-014-2967-4. Epub 2014 Dec 16.

PMID:
25512056
33.

Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.

van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA.

J Mol Diagn. 2015 Jan;17(1):43-52. doi: 10.1016/j.jmoldx.2014.09.005. Epub 2014 Oct 24.

PMID:
25445214
34.

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.

Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Øra I, Schulte JH, Caron HN, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):222-30. doi: 10.1007/s00259-014-2909-1. Epub 2014 Sep 30.

35.

Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases.

Clement SC, Kraal KC, van Eck-Smit BL, van den Bos C, Kremer LC, Tytgat GA, van Santen HM.

J Clin Endocrinol Metab. 2014 Jan;99(1):E112-6. doi: 10.1210/jc.2013-3595. Epub 2013 Dec 4.

PMID:
24187404
36.

Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.

Bleeker G, Schoot RA, Caron HN, de Kraker J, Hoefnagel CA, van Eck BL, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1711-7. doi: 10.1007/s00259-013-2510-z. Epub 2013 Aug 7.

37.

Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.

Clement SC, van Eck-Smit BL, van Trotsenburg AS, Kremer LC, Tytgat GA, van Santen HM.

Pediatr Blood Cancer. 2013 Nov;60(11):1833-8. doi: 10.1002/pbc.24681. Epub 2013 Jul 6.

PMID:
23832530
38.

The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma.

Schoot RA, Bleeker G, Caron HN, van Eck BL, Heij HA, de Kraker J, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1516-22. doi: 10.1007/s00259-013-2455-2. Epub 2013 Jun 6.

39.

Editorial: discrepancies and pitfalls in diagnosis and therapy of esophageal columnar metaplasia/Barrett's esophagus: a personal view.

Tytgat GN.

J Dig Dis. 2013 Aug;14(8):405-8. doi: 10.1111/1751-2980.12071. No abstract available.

PMID:
23672505
40.

[Gastro-highlights 2012].

Bauerfeind P, Schöfl R, Müllhaupt B, Schwizer W, Wirth HP, Rogler G, Fried M, Quigley E, Tytgat GN.

Praxis (Bern 1994). 2013 Feb 13;102(4):197-210. doi: 10.1024/1661-8157/a001224. Review. German.

PMID:
23399603
41.

Response to teszler.

van Santen HM, Tytgat GA, van de Wetering MD, van Eck-Smit BL, Hopman SM, van der Steeg AF, Nieveen van Dijkum EJ, van Trotsenburg AS.

Thyroid. 2013 Feb;23(2):249. doi: 10.1089/thy.2012.0149.rs. Epub 2012 Nov 27. No abstract available.

PMID:
23185983
42.

Endoscopist's view of the future role of the gastroenterologist in digestive oncology.

Tytgat GN.

J Dig Dis. 2013 Mar;14(3):109-12. doi: 10.1111/1751-2980.12015.

PMID:
23167637
43.

Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?

Zwaveling S, Tytgat GA, van der Zee DC, Wijnen MH, Heij HA.

Pediatr Surg Int. 2012 Oct;28(10):953-9. Epub 2012 Jun 22. Review.

44.

Recent developments in gastroesophageal reflux disease and Barrett's esophagus: ANNO 2012.

Tytgat GN.

J Dig Dis. 2012 Jun;13(6):291-5. doi: 10.1111/j.1751-2980.2012.00598.x. Review.

PMID:
22624551
45.

Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.

van Santen HM, Tytgat GA, van de Wetering MD, van Eck-Smit BL, Hopman SM, van der Steeg AF, Nieveen van Dijkum EJ, van Trotsenburg AS.

Thyroid. 2012 Jun;22(6):643-6. doi: 10.1089/thy.2011.0464. Epub 2012 Apr 23.

PMID:
22524499
46.

Panel discussion.

Lam SK, Gasbarrini G, Malfertheiner P, Tytgat GN, Deltenre MA.

Eur J Gastroenterol Hepatol. 2012 Apr;9 Suppl 1:S27-9. No abstract available.

PMID:
22498904
47.

Autoimmune pancreatitis: a novel disease?

Tytgat GN.

J Dig Dis. 2012 May;13(5):243. doi: 10.1111/j.1751-2980.2012.00586.x. No abstract available.

PMID:
22500785
48.

Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.

Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA.

J Mol Diagn. 2012 Mar-Apr;14(2):168-75. doi: 10.1016/j.jmoldx.2011.12.002. Epub 2012 Jan 16.

PMID:
22251610
49.

Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids.

Besançon OG, Tytgat GA, Meinsma R, Leen R, Hoebink J, Kalayda GV, Jaehde U, Caron HN, van Kuilenburg AB.

Cancer Lett. 2012 Jun 1;319(1):23-30. doi: 10.1016/j.canlet.2011.12.016. Epub 2011 Dec 17.

50.

Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.

Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE.

Clin Cancer Res. 2012 Feb 1;18(3):808-14. doi: 10.1158/1078-0432.CCR-11-0849. Epub 2011 Dec 5.

Supplemental Content

Loading ...
Support Center